Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
8 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
119.7 rhumatos / 100 000 hab. — département bien doté
42 publications sur 5 ans
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
12
12 articles ont été cités au moins 12fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
532
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
62
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
12
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre National de la Recherche Scientifique · Inserm · Centre Hospitalier Universitaire de La Réunion
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Impact of nurse navigation and mobile app on brain tumor patients receiving oral anticancer therapy
2026Articlenpj Digital Medicine
Actualités 2025 par le comité de rédaction du Bulletin du Cancer : congrès ASCO, ESMO et au-delà
2025ArticleBulletin du Cancer
Les déterminants de la vaccination anti-papillomavirus humain des garçons à La Réunion : enquête auprès des parents et des médecins généralistes
2025ArticleGynécologie Obstétrique Fertilité & Sénologie
Impact d’une formation sur le papillomavirus au personnel des collèges avant la campagne nationale de vaccination à la Réunion
2025ArticleGynécologie Obstétrique Fertilité & Sénologie
La survie après un cancer à La Réunion
2025ArticleBulletin du Cancer
Recherche Clinique en Oncologie dans les territoires ultramarins
2025ArticleBulletin du Cancer
Descriptive epidemiology of 399 histologically confirmed newly diagnosed meningeal solitary fibrous tumours and haemangiopericytomas in France: 2006-2015
2024ArticleActa Neurochirurgica
Descriptive epidemiology of 30,223 histopathologically confirmed meningiomas in France: 2006–2015
2024ArticleActa Neurochirurgica
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHU SITE SUD (SAINT PIERRE)
AV FRANCOIS MITTERRAND BP 350 TERRE SAINTE, 97410 ST PIERRE
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Diagnostics (Basel, Switzerland) · 2021
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adult patients with a median survival of around one year. Prediction of survival outcomes in GBM patients could represent a huge step in treatment personalization. The objective of this study was to develop machine learning (ML) algorithms for survival prediction of GBM patient. We identified a radiomic signature on a training-set composed of data from the 2019 BraTS challenge (210 patients) from MRI retrieved at diagnosis. Then, using this signature along with the age of the patients for training classification models, we obtained on test-sets AUCs of 0.85, 0.74 and 0.58 (0.92, 0.88 and 0.75 on the training-sets) for survival at 9-, 12- and 15-months, respectively. This signature was then validated on an independent cohort of 116 GBM patients with confirmed disease relapse for the prediction of patients surviving less or more than the median OS of 22 months. Our model insured an AUC of 0.71 (0.65 on train). The Kaplan–Meier method showed significant OS difference between groups (log-rank p = 0.05). These results suggest that radiomic signatures may improve survival outcome predictions in GBM thus creating a solid clinical tool for tailoring therapy in this population.
Diagnostics (Basel, Switzerland) · 2021
Anti-angiogenic therapy with bevacizumab is a widely used therapeutic option for recurrent glioblastoma (GBM). Nevertheless, the therapeutic response remains highly heterogeneous among GBM patients with discordant outcomes. Recent data have shown that radiomics, an advanced recent imaging analysis method, can help to predict both prognosis and therapy in a multitude of solid tumours. The objective of this study was to identify novel biomarkers, extracted from MRI and clinical data, which could predict overall survival (OS) and progression-free survival (PFS) in GBM patients treated with bevacizumab using machine-learning algorithms. In a cohort of 194 recurrent GBM patients (age range 18–80), radiomics data from pre-treatment T2 FLAIR and gadolinium-injected MRI images along with clinical features were analysed. Binary classification models for OS at 9, 12, and 15 months were evaluated. Our classification models successfully stratified the OS. The AUCs were equal to 0.78, 0.85, and 0.76 on the test sets (0.79, 0.82, and 0.87 on the training sets) for the 9-, 12-, and 15-month endpoints, respectively. Regressions yielded a C-index of 0.64 (0.74) for OS and 0.57 (0.69) for PFS. These results suggest that radiomics could assist in the elaboration of a predictive model for treatment selection in recurrent GBM patients.
Journal of clinical medicine · 2020
Scarce data exist on concurrent chemotherapy in locally advanced cervical cancer (LACC) patients (pts) treated with image-guided adaptive brachytherapy (IGABT). We examined the effect of a number of chemotherapy cycles and their interaction with brachytherapy dose/volume parameters. Clinical records of 209 consecutive pts treated for a LACC were reviewed. Pts received CRT concurrently with cisplatin 40 mg/m² or carboplatin AUC2. An additional cycle could have been delivered during the pulse-dose rate (PDR)-IGABT. The impact of a number of chemotherapy cycles on outcome was examined, as well as the interactions with dose volume parameters. The number of cycles was four in 55 (26.3%) pts, five in 154 (73.7%) including 101 receiving the fifth cycle during IGABT. Median follow-up was 5.5 years. Pts receiving five cycles had a better outcome on all survival endpoints, including three year local control rate (93.9% vs. 77.2%; p < 0.05). In the subgroup, only pts with tumor FIGO (Fédération Internationale de Gynécologie Obstétrique) stage ≤IIB or with CTVHR > 25 cm3 had a better outcome. Pts receiving four cycles with D90CTVHR > 80GyEQD2 had the same locoregional control–(LRC) as those receiving five cycles and achieving D90CTVHR ≤ 80 GyEQD2 (p = 0.75). An optimal propensity score matching the balance for the FIGO stage, CTVHR volume and D90CTVHR confirmed the effect, with the largest life expectancy benefit for locoregional failure-free survival (absolute gain: 1.5 years; p = 0.017). Long-term radiation-induced toxicity was not increased. Increasing the total number of cycles from 4 to 5 improved LFS, suggesting a place for systemic strategies aimed at in-field cooperation. Delivering an additional cycle at the time of brachytherapy did not increase morbidity and there permitted an increase in chemotherapy dose intensity.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
European journal of cancer (Oxford, England : 1990) · 2026 · Journal Article
Kalfala E, Meurgey A, Hénon C, Brahmi M, et al.
NPJ digital medicine · 2026 · Journal Article
Poisson C, Duflot-Boukobza A, Mathivon D, Khettab M, et al.
The Pan African medical journal · 2023 · Case Reports
Zidane H, Kebbati Z, Khettab M
Diagnostics (Basel, Switzerland) · 2021 · Journal Article
Ammari S, Sallé de Chou R, Balleyguier C, Chouzenoux E, et al.
Diagnostics (Basel, Switzerland) · 2021 · Journal Article
Ammari S, Sallé de Chou R, Assi T, Touat M, et al.
Journal of clinical medicine · 2020 · Journal Article
Escande A, Khettab M, Bockel S, Dumas I, et al.
Radiology case reports · 2026 · Case Reports
Bahha S, Mrani N, Guennouni A, Aouadi SE, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025 · Journal Article
Nourrit M, Camilleri GM, Couderc AC, Verchain A, et al.